Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Absci (Nasdaq: ABSI), specializing in generative AI for drug creation, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for June 10, 2024, at 2:00 p.m. Eastern Time in Miami, FL. Absci management will present at the conference, which will be accessible via live and archived webcast on the company's investor relations website.
- Participation in a high-profile event, the Goldman Sachs 45th Annual Global Healthcare Conference, enhances Absci's visibility and credibility.
- Scheduled presentation by Absci management on June 10, 2024, can attract potential investors and partners.
- Live and archived webcast availability increases investor engagement and transparency.
- The announcement lacks specific details on financial or operational progress, providing new information that might affect investor decisions.
- No immediate direct financial benefit or new partnerships are mentioned, which could be seen as a missed opportunity.
VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.
Absci management is scheduled to present on Monday, June 10th at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on X (Twitter), LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
What event is Absci (ABSI) participating in?
When will Absci (ABSI) present at the Goldman Sachs Healthcare Conference?
Where can I access the Absci (ABSI) presentation from the Goldman Sachs Conference?
What is the focus of Absci (ABSI)?
